Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M

Journey Medical Corp

Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.
Net product revenues fell 16% to $59.7M due to generic competition and Ximino discontinuation.
Net loss improved to $3.9M ($0.21 loss per share) from $29.6M ($1.69 loss per share) in 2022.
Adjusted EBITDA turned positive to $15.6M ($0.85 basic EPS) from negative $7.3M in 2022.
NDA for rosacea candidate DFD-29 accepted by FDA; PDUFA goal date set for November 4, 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Journey Medical Corp reported the full year ended December 31, 2023 results: revenue $79.2 million, net income $(3.9) million, EPS $(0.21) per share basic and diluted.

Period: the full year ended December 31, 2023
Revenue: $79.2 million
Net income: $(3.9) million
EPS: $(0.21) per share basic and diluted
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Journey Medical Corp filing history →

Source: SEC EDGAR

accession 0001104659-24-037318

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.